Abstracts tagged "COVID-19"

Abstract Number: 0793 • ACR Convergence 2022
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
Norman Gaylis¹, Odense DeLaRosa¹, Nayak Polissar², Nirnaya Miljacic² and Andrew Holman³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Mountain Whisper Light, Seattle, WA, ³Inmedix Inc, Seattle, WA
Background/Purpose: Up to 70% of the 236 million people who have been diagnosed with SARS-CoV-2 develop post-COVID symptoms. (1) This has been defined by the…
Abstract Number: 0950 • ACR Convergence 2022
Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
Sinead Maguire¹, Samar Al emadi², Paul Alba³, Mathia C Aguiar⁴, Talal Al Lawati⁵, Gelsomina Alle⁶, Bonnie Bermas⁷, Suleman Bhana⁸, Branimir Anic⁹, Inita Bulina¹⁰, Megan Clowse¹¹, Adriana Karina Cogo¹², Iris Colunga¹³, Claire Cook¹⁴, KAREN JOYCE CORTEZ¹⁵, Kathryn Dao¹⁶, Milena Gianfrancesco¹⁷, Monique Gore-Massy¹⁸, Laure Gossec¹⁹, Rebecca Grainger²⁰, Jonathan Hausmann²¹, Tiffany YT Hsu²², Kimme Hyrich²³, Carolina Isnardi²⁴, Yumeko Kawano²², Rachael Kilding²⁵, Daria A Kusevich²⁶, Saskia Lawson-Tovey²⁷, Jean Liew²⁸, Eoghan McCarthy²⁹, Anna Montgomery³⁰, Sebastian Moyano³, Noreen Nasir³¹, IVAN PADJEN³², Charalampos Papagoras³³, Naomi Patel³⁴, MARIANA PERA³⁵, Cecilia Pisoni³⁶, Guillermo Pons-Estel³⁷, Antonio Lorenzo Quiambao³⁸, Rosana Quintana³⁹, Eric Ruderman⁴⁰, Sebastian Sattui⁴¹, Veronica Savio⁴², Savino Sciascia⁴³, Marieta Sencarova⁴⁴, Rosa Serrano-Morales⁴⁵, Faizah Siddique⁴⁶, Emily Sirotich⁴⁷, Jeffrey Sparks⁴⁸, Anja Strangfeld⁴⁹, Paul Sufka⁵⁰, Helen Tanner⁵¹, Yohana Tissera⁵², Zachary Wallace¹⁴, Marina Werner⁵³, Leanna Wise⁵⁴, Angus Worthing⁵⁵, JoAnn Zell⁵⁶, Julija Zepa¹⁰, Pedro Machado⁵⁷, Jinoos Yazdany¹⁷, Philip Robinson⁵¹ and Richard Conway¹,¹St James' Hospital, Dublin, Ireland, ²Hamad Medical Corporation, Doha, Qatar, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital General Agustin O`Horan, Merida, Mexico, ⁵Sultan Qaboos University Hospital, Muscat, Oman, ⁶Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷UT Southwestern, Dallas, TX, ⁸Crystal Run Healthcare, Middletown, NY, ⁹Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, ¹⁰Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, ¹¹Duke University, Durham, NC, ¹²Hospital Interzonal Luis Guemes, Haedo and Hospital San Juan de Dios, Castelar, Buenos Aires, Argentina, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Massachusetts General Hospital, Boston, MA, ¹⁵Baguio General Hospital Medical Center, Baguio, Philippines, ¹⁶UT Southwestern Medical Center, Dallas, TX, ¹⁷University of California San Francisco, San Francisco, CA, ¹⁸Covid-19 GRA, West Orange, NJ, ¹⁹Sorbonne Université, Paris, France, ²⁰University of Otago, Wellington, New Zealand, ²¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²²Brigham and Women's Hospital, Boston, MA, ²³The University of Manchester, Manchester, United Kingdom, ²⁴SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ²⁵Sheffield teaching hospitals trust, Sheffield, United Kingdom, ²⁶VA Nasonova Research Institute of Rheumatology, Moscow and Anikina Clinic, Vidnoe, Russia, ²⁷Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²⁸Boston University, Boston, MA, ²⁹Beaumont Hospital, Dublin, Ireland, ³⁰University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, ³¹Aga Khan University Hospital, Karachi Pakistan, Karachi, Pakistan, ³²University Hospital Center Zagreb, Zagreb, Croatia, ³³First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ³⁴Massachusetts General Hospital, Sale Creek, TN, ³⁵Hospital Ángel C Padilla, San Miguel de Tucumán, Tucuman, Argentina, ³⁶CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ³⁷Argentine Society of Rheumatology, Buenos Aires, Argentina, ³⁸East Avenue Medical Center, Quezon City, Philippines, ³⁹Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁴⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴¹University of Pittsburg, Pittsburg, Pennsylvania, USA, PIttsburgh, PA, ⁴²Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, ⁴³University of Turin, Torino, Italy, ⁴⁴Univerzitna nemocnica L Pasteura, Slovakia, Kosice, Slovakia, ⁴⁵Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, ⁴⁶Loyola University Medical Center, Elmhurst, IL, ⁴⁷Department of Health Research, Evidence and Impact, McMaster University, Hamilton, ON, Canada, ⁴⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴⁹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁵⁰HealthPartners, Eagan, MN,⁵¹University of Queensland School of Medicine, Brisbane, Queensland, Australia, ⁵²Internal Medicine Service, Rheumatology Unit, Hospital Córdoba y Sanatorio Parque de Córdoba, Córdoba, Argentina, ⁵³Hospital Nacional de Clínicas, Córdoba, Argentina, ⁵⁴LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁵⁵Arthritis & Rheumatism Associates, PC, Washington, DC, ⁵⁶University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London and National Institute for Health Research (NIHR), University College London Hospitals NHS Foundation Trust, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
Background/Purpose: To describe obstetric outcomes based on COVID-19 vaccination status in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.Methods: We extracted…
Abstract Number: 1330 • ACR Convergence 2022
Impact of COVID-19 Severity on Physical Function, Mobility, Falls and Fractures Among Older Patients After Hospitalization: A Longitudinal Study
Clara Wong¹, Diego Cabrera², Mary Geda³, Andrew Cohen³, Lauren Ferrante³, Alexandra Hajduk³ and Evelyn Hsieh², ¹Yale School of Public Health, New Haven, CT, ²Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, ³Yale School of Medicine, New Haven, CT
Background/Purpose: No longitudinal studies have examined the impact of COVID-19 or COVID-19 severity on physical function and disability outcomes among older adults. Multiple factors, including…
Abstract Number: 1766 • ACR Convergence 2022
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Angie El-Said¹, Areeb Ahmad², Massimo Valenti³, Neel K. Shah¹, Susana Soto¹ and Shazia Beg⁴, ¹University of Central Florida College of Medicine, Orlando, FL, ²University of Central Florida, Orlando, FL, ³Sapienza University of Rome, School of Medicine, Rome, Italy, ⁴UCF, Orlando, FL
Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…
Abstract Number: 1939 • ACR Convergence 2022
Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases
Merav Heshin-Bekenstein¹, amit ziv², NATASA TOPLAK³, Adi Miller Barmak⁴, Siman Lazauskas⁵, Danielle Kadishevich⁶, Efrat Ben Nun⁶, Esther Saiag⁷, Yonatan Butbul Aviel⁴, Gabi Shefer⁷, Sara Pel⁸, Ori Elkayam⁷ and Yosef Uziel⁹, ¹Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ²Meir Hospital, Kfar Saba, Israel, ³University of Ljubljana, Ljubljana, Slovenia, ⁴Rambam Medical Center, Haifa, Israel, ⁵Tel Aviv Medical Center, Tel Aviv, Israel, ⁶Meir Medical Center, Kfar Saba, Israel, ⁷Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁸Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
Background/Purpose: Long-term data on the safety and dynamics of the immune response to the BNT162b2 mRNA COVID-19 vaccine in adolescents with juvenile-onset autoimmune inflammatory rheumatic…
Abstract Number: 2273 • ACR Convergence 2022
Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study
Amy Mudano¹, Gary Cutter², Ted Mikuls³, Geoffrey Thiele⁴, Mark Law⁴, Bart Hamilton⁴, Michael Zikry⁵, Kelly Y. Chun⁶, Monique Bastidas⁷, Michael George⁸, Lisa Williams⁹, Kevin Winthrop¹⁰, Mark Busch¹¹, Stanley Cohen¹², Roman Czubatyj¹³, Rajesh Kataria¹⁴, Reshma Khan¹⁵, Soha Mousa¹⁶, Jose Pando¹⁷, Elizabeth Perkins¹⁸, Shanmugapriya Reddy¹⁹, Delfin Santos²⁰, Joy Schechtman²¹, Frank Scott²², Sucharitha Shanmugam²³, Atul Singhal²⁴, John Tesser²⁵, John Tower²⁶, Swamy Venuturupalli²⁷, Sean Joseph Wollaston²⁸, Conrad Ziembinski²⁹ and Jeffrey Curtis³⁰, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵LabCorp, Burlington, NC, ⁶Labcorp, Calabasas, CA, ⁷LabCorp, Northridge, CA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Illumination Heath, Hoover, AL, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹Family Arthritis Center-Jupiter, Jupiter, FL, ¹²Metroplex Clinical Research Center, Pittsburgh, PA, ¹³Arthritis Physicians LLC, Rochester Hills, MI, ¹⁴Southern Ohio, Wheelersburg, OH, ¹⁵Palm Beach Rheumatology and Wellness, Jupiter, FL, ¹⁶Arthritis and Rheumatology of Southwest Ohio, Liberty Township, OH, ¹⁷Rheumatology Consultants of DE, Lewes, DE, ¹⁸Rheumatology Care Center, Hoover, AL, ¹⁹Southwest Florida Rheumatology, Riverview, FL, ²⁰Rochester Rheumatology, Rochester Hills, MI, ²¹SunValley Arthritis Center, Peoria, AZ, ²²Arthritis Medical Center, Arroyo Grande, CA, ²³Rheumatology and Arthritis Care Center, Exton, PA, ²⁴Southwest Rheumatology Research, Mesquite, TX, ²⁵Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²⁶Arthritis Physicians LLC, Rochester, MI, ²⁷Cedars-Sinai Medical Center, Los Angeles, CA, ²⁸Rheumatology Associates, North Hollywood, CA, ²⁹CZ Rheumatology, Coral Springs, FL, ³⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…
Abstract Number: 0253 • ACR Convergence 2022
Evaluation of Patients with Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic
Jérôme Avouac¹, Anna Molto², Camelia Frantz³, sarah wanono³, elise descamps⁴, olivier fogel⁴, Alice Combier⁵, lucile poiroux⁵, Corinne MIceli⁶ and Yannick Allanore⁷, ¹University of Paris, Paris, France, ²Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France, ³Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Hôpital Cochin, AP-HP Centre - Université de Paris Cité, Paris, France, ⁵Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, ⁶APHP, Paris, France, ⁷Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The sudden emergence of SARS-CoV-2 onto the world stage has accelerated a major change in the management of patients with chronic rheumatic diseases and…
Abstract Number: 0705 • ACR Convergence 2022
Severity of SARS-CoV-2 Omicron Breakthrough Infections in Patients with Rheumatic Immune-mediated Inflammatory Diseases and Healthy Controls: Data from a Prospective Cohort Study
Laura Boekel¹, Yaëlle Besten¹, Femke Hooijberg¹, Rosa Wartena¹, Maurice Steenhuis², Erik Vogelzang³, Maureen Leeuw¹, Sadaf Atiqi¹, Sander Tas⁴, Willem Lems⁵, Marieke van Ham², Filip Eftimov³, Eileen Stalman³, Luuk Wieske³, Taco Kuijpers³, Alexandre Voskuyl⁶, Ronald van Vollenhoven⁷, Martijn Gerritsen¹, Charlotte Krieckaert¹, Theo Rispens², Maarten Boers⁸, Michael Nurmohamed⁹ and Gertjan Wolbink¹, ¹Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ²Sanquin Research, Amsterdam, Netherlands, ³Amsterdam UMC, location AMC, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center, location AMC, Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center, location VUMC, Amsterdam, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁹Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: The Omicron (B.1.1.529) variant of SARS-CoV-2 is associated with substantially lower hospitalization rates compared with previous variants of SARS-CoV-2 (i.e., Wildtype, Alpha [B.1.1.7] and…
Abstract Number: 0773 • ACR Convergence 2022
Additional Dose of SARS-CoV-2 Vaccine Improves Cross-Variant Neutralization Titers in Immunosuppressed Patients with Chronic Inflammatory Disease
Michael Paley¹, Parakkal Deepak², Wooseob Kim³, Monica Yang⁴, Vinay Chandrasekaran³, Guadalupe Oliva Escudero³, Katherine Huang³, Zhuoming Liu³, Lily McMorrow⁵, Mahima Thapa³, Matthew Ciorba³, Mehrdad Matloubian⁶, Lianne Gensler⁷, Mary Nakamura⁸, Sean Whelan³, William Buchser³, Ali Ellebedy³ and Alfred Kim⁵, ¹Washington University in St. Louis, Saint Louis, MO, ²Washington University in St. Louis, Saint Louis, ³Washington University in St. Louis, St. Louis, MO, ⁴UCSF, SF, CA, ⁵Washington University School of Medicine, St. Louis, MO, ⁶UCSF, San Francisco, CA, ⁷Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁸UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Most immunosuppressed patients with chronic inflammatory diseases (CID) mount total anti-Spike (S) IgG responses following vaccination with mRNA-based SARS-CoV-2 vaccines. Less is known, however,…
Abstract Number: 0794 • ACR Convergence 2022
Impact of Vaccination on Post-acute Sequelae of SARS CoV-2 Infection in Patients with Rheumatic Diseases
Naomi Patel¹, Yumeko Kawano², Xiaosong Wang², Xiaoqing Fu³, Claire Cook³, Kathleen Vanni², Grace Qian², Emily Banasiak², Emily Kowalski², yuqing zhang⁴, Jeffrey Sparks⁵ and Zachary Wallace³, ¹Massachusetts General Hospital, Sale Creek, TN, ²Brigham and Women's Hospital, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Post-acute sequelae of COVID-19 (PASC) refers to persistent symptoms after the resolution of acute infection and is estimated to affect over 20% of COVID-19…
Abstract Number: 0991 • ACR Convergence 2022
Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
Cassandra Calabrese¹, Gelareh Atefi², Kristin Evans³, Meghan Moynihan³, Liisa Palmer³ and Sandra Sze-jung Wu⁴, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²AstraZeneca, Wilmington, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, Hockessin, DE
Background/Purpose: To compare use of autoimmune disease treatments between patients with and without severe COVID-19 (COVID) in cohorts of patients with systemic lupus erythematosus (SLE),…
Abstract Number: 1339 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
Matthew Wong-Pack¹, Elliot Hepworth², Mohammad Movahedi³, Bindee Kuriya¹, Janet Pope⁴, Edward Keystone⁵, Carter Thorne⁶, VANDANA AHLUWALIA⁷, Angela Cesta⁸, Carol Mously⁸, Claire Bombardier¹, Arthur Lau⁹ and Sibel Aydin¹⁰, ¹University of Toronto, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷William Osler Health System, Brampton, ON, Canada, ⁸University Health Network, Toronto, ON, Canada, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada
Background/Purpose: The COVID-19 Pandemic created challenges for patients with rheumatoid arthritis (RA), including accessing the health care system, transition to unplanned virtual care, reduction in…
Abstract Number: 1776 • ACR Convergence 2022
COVID-19 Cases in Patients Treated with Secukinumab: Analysis from the Global Safety Database
Atul Deodhar¹, Andrew Blauvelt², Philip J Mease³, Effie Pournara⁴, Piotr Jagiello⁴, Weibin Bao⁵ and Abhishek Sharma⁶, ¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ²Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Healthcare Pvt. Ltd, Hyderabad, India
Background/Purpose: Although patients (pts) with immune-mediated inflammatory diseases who are taking immunosuppressive therapies are not at a significantly greater risk of SARS-CoV-2 (severe acute respiratory…
Abstract Number: 1949 • ACR Convergence 2022
Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases
amit ziv¹, Merav Heshin-Bekenstein², Ruby Haviv³, Shaye Kivity⁴, doron netzer⁵, shlomit yaron⁵, yoav schur⁵, tsipi egert⁶, yona egert⁶, yaron sela⁷, Philip Hashkes⁸ and Yosef Uziel⁹, ¹Meir Hospital, Kfar Saba, Israel, ²Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ³Meir Medical Center, Ra'Anana, Israel, ⁴Meir Medical Center, Kefar Saba, Israel, ⁵Community Medical Services Division, Clalit Health Services, Tel Aviv, Israel, ⁶Inbar, NPO, Ramat Gan, Israel, ⁷The Research Center for Internet Psychology, School of Communications, Reichman University, Herzliya, Israel, ⁸Shaare Zedek Medical Center, Jerusalem, Israel, ⁹Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel
Background/Purpose: Effectiveness of the BNT162b2 mRNA COVID-19 vaccine for adolescents with juvenile-onset inflammatory rheumatic diseases (IRD) is unknown. Several studies suggested attenuated immunogenicity in patients…
Abstract Number: 2274 • ACR Convergence 2022
Factors Associated with Disease Flare Following SARS-CoV-2 Vaccination in People with Inflammatory Rheumatic and Musculoskeletal Diseases – Results from the Physician-Reported EULAR Coronavirus Vaccine (COVAX) Registry
Bayram Farisoğulları¹, Saskia Lawson-Tovey², Kimme Hyrich³, Laure Gossec⁴, Loreto Carmona⁵, Anja Strangfeld⁶, Elsa Mateus⁷, Martin Schaefer⁸, Ana Maria Rodrigues⁹, Eric Hachulla¹⁰, Jose A Gomez-Puerta¹¹, Marta Mosca¹², Patrick Durez¹³, Ludovic Trefond¹⁴, Tiphaine Goulenok¹⁵, Martina Cornalba¹⁶, Emoke Šteňová¹⁷, Inita Bulina¹⁸, Eva Strakova¹⁹, Julija Zepa²⁰, Nicolas Roux²¹, Olivier Brocq²², Viellard Eric²³, Bernd Raffeiner²⁴, Gerd Burmester²⁵, Xavier Mariette²⁶ and Pedro Machado²⁷, ¹Hacettepe University Faculty of Medicine Division of Rheumatology, Ankara, Turkey, ²Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴Sorbonne Université, Paris, France, ⁵Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁷EULAR, Lisboa, Portugal, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ¹⁰University of Lille, LILLE, France, ¹¹Hospital Clínic de Barcelona, Barcelona, Spain, ¹²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹³Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ¹⁴Université Clermont Auvergne, CHU Clermont-Ferrand, Service de Médecine Interne, Hôpital Gabriel Montpied, INSERM U1071, Clermont-Ferrand, France, ¹⁵APHP, Paris, France, ¹⁶Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Milano, Italy, ¹⁷University Hospital, Bratislava, Slovakia, ¹⁸Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, Riga, Latvia, ¹⁹Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, ²⁰Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, ²¹Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, ²²Rheumatology- CH Princesse Grace, Monaco, Monaco, ²³Private practice, St. Malo, France, ²⁴Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, ²⁵Charité University Medicine Berlin, Berlin, Germany, ²⁶Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²⁷University College London, London, United Kingdom
Background/Purpose: To investigate the frequency and factors associated with disease flare following vaccination against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMD).Methods: The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].